Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial by Lucia Bailón, José Moltó, Adrian Curran, Julen Cadiñanos, Juan Carlos Lopez Bernaldo de Quirós, Ignacio de Los Santos, Juan Ambrosioni, Arkaitz Imaz, Susana Benet, Paula Suanzes, Jordi Navarro, Juan González-García, Carmen Busca, Leire Pérez-Latorre, Juan Berenguer, Lucio Jesús García-Fraile, Gina Mejía-Abril, Jose M. Miró, Sofía Scévola, Santiago Moreno, Pere Domingo, Yuan Tian, Michelle Frankot, Daina Lim, Yanhui Cai, Elena Vendrame, Susan Guo, Jeffrey J. Wallin, Romas Geleziunas, Devi SenGupta, Yovaninna Alarcón-Soto, Isabel Leal, Alvaro Aranguen, Margarida Garcia-Garcia, Ian McGowan, Christian Brander, Jose Ramón Arribas, Beatriz Mothe, On behalf of the AELIX-003 Study Group

Get full text